Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp215 | Reproduction | ECE2018

Alleviation of perfluorooctanesulfonate (PFOS)-induced disruption of blood-testis barrier by altering cell signaling molecule expression in human sertoli cells.

Chen H , Cheng CY , Lee WM

Perfluorooctanesulfonate (PFOS) and its related product perfluorooctanic acid (PFOA) are anthropogenic fluorosurfactants widely used in consumer products. In general, studies in rodents have supported the conception that PFOS perturbs testis function, such as by inducing Sertoli cell injury. It remains to be demonstrated if similar effects could be reproduced in humans. We sought to examine its effects on human spermatogenesis by using a human Sertoli cell primary culture syst...

ea0007p47 | Diabetes, metabolism and cardiovascular | BES2004

A novel non-steroidal inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models

Thieringer R , Balkovec J , Chen H , Frazier E , Le Grand C , Li Z , Metzger J , Mundt S , Nunes C , Strowski M , Olson S , Robertson N , Strack A , Schaeffer J , Wright S , Zhang B , Hermanowski-Votska A

Chronic exposure to elevated circulating glucocorticoids can lead to metabolic changes, which resemble those observed in Metabolic Syndrome. Features of the Metabolic Syndrome can be reversed by lowering systemic glucocorticoid levels or by treatment with a glucocorticoid receptor antagonist. At the intracellular level, exposure to glucocorticoids is regulated by two distinct 11beta-hydroxysteroid dehydrogenases, 11beta-HSD type 1 and type 2. 11beta-HSD1 predominantly acts as ...